Expres2ion Biotech Holding Stock Price To Earnings To Growth
| EXPRS2 Stock | SEK 21.60 4.60 17.56% |
ExpreS2ion Biotech Holding fundamentals help investors to digest information that contributes to ExpreS2ion Biotech's financial success or failures. It also enables traders to predict the movement of ExpreS2ion Stock. The fundamental analysis module provides a way to measure ExpreS2ion Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ExpreS2ion Biotech stock.
ExpreS2ion |
ExpreS2ion Biotech Holding Company Price To Earnings To Growth Analysis
ExpreS2ion Biotech's PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Based on the latest financial disclosure, ExpreS2ion Biotech Holding has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to earnings to growth for all Sweden stocks is 100.0% higher than that of the company.
Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
ExpreS2ion Fundamentals
| Return On Equity | -0.97 | |||
| Return On Asset | -0.55 | |||
| Operating Margin | (20.75) % | |||
| Current Valuation | 361.15 M | |||
| Shares Outstanding | 37.15 M | |||
| Shares Owned By Institutions | 1.75 % | |||
| Price To Book | 3.42 X | |||
| Price To Sales | 55.94 X | |||
| Revenue | 12.23 M | |||
| Gross Profit | 1.07 M | |||
| EBITDA | (45.5 M) | |||
| Net Income | (43.92 M) | |||
| Cash And Equivalents | 10.14 M | |||
| Cash Per Share | 0.75 X | |||
| Total Debt | 3.48 M | |||
| Debt To Equity | 10.40 % | |||
| Current Ratio | 2.62 X | |||
| Book Value Per Share | 2.75 X | |||
| Cash Flow From Operations | (45.65 M) | |||
| Earnings Per Share | (1.55) X | |||
| Number Of Employees | 14 | |||
| Beta | 1.25 | |||
| Market Capitalization | 487.85 M | |||
| Total Asset | 151.96 M | |||
| Z Score | 84.0 | |||
| Net Asset | 151.96 M |
About ExpreS2ion Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ExpreS2ion Biotech Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ExpreS2ion Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ExpreS2ion Biotech Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in ExpreS2ion Stock
ExpreS2ion Biotech financial ratios help investors to determine whether ExpreS2ion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ExpreS2ion with respect to the benefits of owning ExpreS2ion Biotech security.